![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Aripiprazole.
|
This is the
talk page for discussing improvements to the
Aripiprazole article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives:
1Auto-archiving period: 180 days
![]() |
![]() | This article is rated B-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
![]() | This article is substantially duplicated by a piece in an external publication. Please do not flag this article as a copyright violation of the following source:
|
![]() | Text and/or other creative content from Aripiprazole was copied or moved into List of side effects of aripiprazole with this edit. The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted as long as the latter page exists. |
![]() | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
alcohols are classified but caffeine's have yet to be put into a class I would go as far as to say the presence of oxygen make's this a chlorite and the molecule structure makes it a caffeine and that explains one of the most common side effects "the jitters" 2001:558:6012:1B:3576:163:83B8:C668 ( talk) 14:45, 29 July 2018 (UTC)
I'm concerned about what seems like an anti-medication bias throughout this article, emaphasizing flawed studies and studies with equivocal results and apparently disregarding the documentation, which is extensive, of aripiprazole's utility in clinical practice. I think this article would need an expert to correct this, however. Ucbuffalo81 ( talk) 19:12, 22 October 2018 (UTC)
Ucbuffalo81 ( talk) 19:17, 22 October 2018 (UTC)
IMO belongs in the body of the text. Also trimmed a bunch of the primary sources. Doc James ( talk · contribs · email) 22:19, 5 May 2019 (UTC)
This IMO is undue weight and overly detailed for the lead. And no it is not accessible.
"Known aripiprazole's mechanism of action is different from those of the other atypical antipsychotics [1] [2] [3] [4] [5] [6] [7] [8]. It shows differential engagement at the dopamine (D2 [1] It appears to show predominantly antagonist activity on postsynaptic D2 receptors and partial agonist activity on presynaptic D2 receptors. [9], D3 [1] [10] [11], and partially D4 [1] [3]) and is a partial stimulant of serotonin ( 5-HT1A [1] [12] [13], 5-HT2A [1], 5-HT2B [1], 5-HT6, and 5-HT7 [1] [8]). It also shows lower and likely insignificant effect on histamine ( H1), epinephrine/norepinephrine (α), and otherwise dopamine ( D4), as well as the serotonin transporter [1] [3]. Aripiprazole acts by modulating neurotransmission overactivity of dopamine, which is thought to mitigate schizophrenia symptoms [14]."
Doc James ( talk · contribs · email) 04:49, 6 May 2019 (UTC)
"Known aripiprazole's mechanism of action is different from those of the other atypical antipsychotics [1] [2] [3] [4] [5] [6] [7] [8]. It shows differential engagement at the dopamine (D2 [1] It appears to show predominantly blocking activity on receiving D2 receptors and partial stimulating activity on sending D2 receptors. [9], D3 [1] [10] [11], and partially D4 [1] [3]) and is a partial stimulant of serotonin ( 5-HT1A [1] [12] [13], 5-HT2A [1], 5-HT2B [1], 5-HT6, and 5-HT7 [1] [8]). It also shows lower and likely insignificant effect on histamine ( H1), epinephrine/norepinephrine (α), and otherwise dopamine ( D4), as well as the serotonin transporter [1] [3]. Aripiprazole acts by modulating neurotransmission overactivity of dopamine, which is thought to mitigate schizophrenia symptoms [14]."
"Known aripiprazole's mechanism of action is different from those of the other atypical antipsychotics [1] [2] [3] [4] [5] [6] [7] [8]. Aripiprazole modulates overactivity of dopamine, which is thought to mitigate schizophrenia symptoms [14]. Specifically, it shows differential engagement at the dopamine (D2 [1]: can block activity on receiving D2 receptors and partially stimulate on sending D2. [9], D3 [1] [10] [11], and partially D4 [1] [3]) and is a partial stimulant of serotonin ( 5-HT1A [1] [12] [13], 5-HT2A [1], 5-HT2B [1], 5-HT6, and 5-HT7 [1] [8]). But, it shows min. effect on histamine ( H1), epinephrine/norepinephrine (α), and otherwise dopamine ( D4), as well as the serotonin transporter [1] [3]."
References
pmid12784105
was invoked but never defined (see the
help page).drugLabelPC
was invoked but never defined (see the
help page).pmid17728427
was invoked but never defined (see the
help page).Cochrane reviewers and their publishing should be limited to wikipedia.co.uk rather than USA wikipedia. The UK and their MHRA are many years behind the usa and the fda. USA doctors who conduct clinical trials in the usa are bound by the american academy of psychiatry, usa law, and general researcher ethics. If you want to cite and support (non-peer reviewed) cochrane and uk reviewers, then you might as well cite them to discredit all usa fda drugs that aren't approved in the UK. However, as a general rule, for Cochrane studies, the arguments are that [1] there is "bias" from these ethically bound doctors because they are pharmacy funded studies, [2] because there is this "bias" they are "low quality," and thus, discreditable if not dismissible, [3] there ought not be a dropout rate in any antipsychotic studies because all antipsychotics are on the assumption for being highly tolerable in the first place. Indeed, from this assumption, it is shocking that there is any dropout rate and low tolerance for something that used to be referred to more as "major tranquilizers." Why would people not tolerate tranquilizers? Don't they want to sleep lots? Why would anyone not be medicine compliant for such medication. For [1] the doctors and researchers are bias rather than outright liars and frauds with doctor licenses because they are too naive and stupid to be objective. Arguably, it takes something of more self and social awareness to be an outright liar and fraud than someone to be bias; thus, these license and ethically bound doctors must be the latter. For [2], citing, what I see as anti psychiatry, in this regard merits criticism against the greater funding process for clinical trials in the first place. Indeed, perhaps if the usa were less freemarket, then perhaps usa clinical trials could have direct government supervision and funding rather than from pharmacy companies that likely get some government grants. However, the healthcare system and research is not centralized in this way. This relates more to the greater economic and healthcare structural system than picking on all individual pharmacy studies which all have this funding structure issue. Rather, it is collective and exist in all studies. Note, i would not compare and be harsh against the UK and MHRA compared to the usa fda if there isn't an apparent anti psychiatry movement going on as i see it.
@ Whywhenwhohow: In 9 edits, I have made 7 additions to the article. They are well-sourced. You have reverted every single time. Explain yourself. You can't keep reverting with falsehoods like implying I said children, adolescents and young adults are elderly. < sic>
“ | "WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS AND SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS." --Abilify black box warning's initial sentence, which appears with all caps emphasis in original. |
” |
And particularly relevant to your claim putting words in my mouth:
“ | "• Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. " --Abilify black box warning. |
” |
I brought this up on your talk page on the 21s of last month! RudolfoMD ( talk) 03:36, 4 November 2023 (UTC)
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Aripiprazole.
|
This is the
talk page for discussing improvements to the
Aripiprazole article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives:
1Auto-archiving period: 180 days
![]() |
![]() | This article is rated B-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
![]() | This article is substantially duplicated by a piece in an external publication. Please do not flag this article as a copyright violation of the following source:
|
![]() | Text and/or other creative content from Aripiprazole was copied or moved into List of side effects of aripiprazole with this edit. The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted as long as the latter page exists. |
![]() | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
alcohols are classified but caffeine's have yet to be put into a class I would go as far as to say the presence of oxygen make's this a chlorite and the molecule structure makes it a caffeine and that explains one of the most common side effects "the jitters" 2001:558:6012:1B:3576:163:83B8:C668 ( talk) 14:45, 29 July 2018 (UTC)
I'm concerned about what seems like an anti-medication bias throughout this article, emaphasizing flawed studies and studies with equivocal results and apparently disregarding the documentation, which is extensive, of aripiprazole's utility in clinical practice. I think this article would need an expert to correct this, however. Ucbuffalo81 ( talk) 19:12, 22 October 2018 (UTC)
Ucbuffalo81 ( talk) 19:17, 22 October 2018 (UTC)
IMO belongs in the body of the text. Also trimmed a bunch of the primary sources. Doc James ( talk · contribs · email) 22:19, 5 May 2019 (UTC)
This IMO is undue weight and overly detailed for the lead. And no it is not accessible.
"Known aripiprazole's mechanism of action is different from those of the other atypical antipsychotics [1] [2] [3] [4] [5] [6] [7] [8]. It shows differential engagement at the dopamine (D2 [1] It appears to show predominantly antagonist activity on postsynaptic D2 receptors and partial agonist activity on presynaptic D2 receptors. [9], D3 [1] [10] [11], and partially D4 [1] [3]) and is a partial stimulant of serotonin ( 5-HT1A [1] [12] [13], 5-HT2A [1], 5-HT2B [1], 5-HT6, and 5-HT7 [1] [8]). It also shows lower and likely insignificant effect on histamine ( H1), epinephrine/norepinephrine (α), and otherwise dopamine ( D4), as well as the serotonin transporter [1] [3]. Aripiprazole acts by modulating neurotransmission overactivity of dopamine, which is thought to mitigate schizophrenia symptoms [14]."
Doc James ( talk · contribs · email) 04:49, 6 May 2019 (UTC)
"Known aripiprazole's mechanism of action is different from those of the other atypical antipsychotics [1] [2] [3] [4] [5] [6] [7] [8]. It shows differential engagement at the dopamine (D2 [1] It appears to show predominantly blocking activity on receiving D2 receptors and partial stimulating activity on sending D2 receptors. [9], D3 [1] [10] [11], and partially D4 [1] [3]) and is a partial stimulant of serotonin ( 5-HT1A [1] [12] [13], 5-HT2A [1], 5-HT2B [1], 5-HT6, and 5-HT7 [1] [8]). It also shows lower and likely insignificant effect on histamine ( H1), epinephrine/norepinephrine (α), and otherwise dopamine ( D4), as well as the serotonin transporter [1] [3]. Aripiprazole acts by modulating neurotransmission overactivity of dopamine, which is thought to mitigate schizophrenia symptoms [14]."
"Known aripiprazole's mechanism of action is different from those of the other atypical antipsychotics [1] [2] [3] [4] [5] [6] [7] [8]. Aripiprazole modulates overactivity of dopamine, which is thought to mitigate schizophrenia symptoms [14]. Specifically, it shows differential engagement at the dopamine (D2 [1]: can block activity on receiving D2 receptors and partially stimulate on sending D2. [9], D3 [1] [10] [11], and partially D4 [1] [3]) and is a partial stimulant of serotonin ( 5-HT1A [1] [12] [13], 5-HT2A [1], 5-HT2B [1], 5-HT6, and 5-HT7 [1] [8]). But, it shows min. effect on histamine ( H1), epinephrine/norepinephrine (α), and otherwise dopamine ( D4), as well as the serotonin transporter [1] [3]."
References
pmid12784105
was invoked but never defined (see the
help page).drugLabelPC
was invoked but never defined (see the
help page).pmid17728427
was invoked but never defined (see the
help page).Cochrane reviewers and their publishing should be limited to wikipedia.co.uk rather than USA wikipedia. The UK and their MHRA are many years behind the usa and the fda. USA doctors who conduct clinical trials in the usa are bound by the american academy of psychiatry, usa law, and general researcher ethics. If you want to cite and support (non-peer reviewed) cochrane and uk reviewers, then you might as well cite them to discredit all usa fda drugs that aren't approved in the UK. However, as a general rule, for Cochrane studies, the arguments are that [1] there is "bias" from these ethically bound doctors because they are pharmacy funded studies, [2] because there is this "bias" they are "low quality," and thus, discreditable if not dismissible, [3] there ought not be a dropout rate in any antipsychotic studies because all antipsychotics are on the assumption for being highly tolerable in the first place. Indeed, from this assumption, it is shocking that there is any dropout rate and low tolerance for something that used to be referred to more as "major tranquilizers." Why would people not tolerate tranquilizers? Don't they want to sleep lots? Why would anyone not be medicine compliant for such medication. For [1] the doctors and researchers are bias rather than outright liars and frauds with doctor licenses because they are too naive and stupid to be objective. Arguably, it takes something of more self and social awareness to be an outright liar and fraud than someone to be bias; thus, these license and ethically bound doctors must be the latter. For [2], citing, what I see as anti psychiatry, in this regard merits criticism against the greater funding process for clinical trials in the first place. Indeed, perhaps if the usa were less freemarket, then perhaps usa clinical trials could have direct government supervision and funding rather than from pharmacy companies that likely get some government grants. However, the healthcare system and research is not centralized in this way. This relates more to the greater economic and healthcare structural system than picking on all individual pharmacy studies which all have this funding structure issue. Rather, it is collective and exist in all studies. Note, i would not compare and be harsh against the UK and MHRA compared to the usa fda if there isn't an apparent anti psychiatry movement going on as i see it.
@ Whywhenwhohow: In 9 edits, I have made 7 additions to the article. They are well-sourced. You have reverted every single time. Explain yourself. You can't keep reverting with falsehoods like implying I said children, adolescents and young adults are elderly. < sic>
“ | "WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS AND SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS." --Abilify black box warning's initial sentence, which appears with all caps emphasis in original. |
” |
And particularly relevant to your claim putting words in my mouth:
“ | "• Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. " --Abilify black box warning. |
” |
I brought this up on your talk page on the 21s of last month! RudolfoMD ( talk) 03:36, 4 November 2023 (UTC)